MYCN and lymphoma: In fact, MLN8237 is currently in clinical testing in patients with advanced solid tumors, lymphoma and acute myelogenous leukemia.45, 46, 47 Preliminary results showed that 17% of AML patients (6/35) acquired treatment response.47 In general, our findings offer strategies to develop future therapies for MYCN-overexpressed erythroleukemia and other MYCN- dependent leukemia.